BioCentury
ARTICLE | Company News

Notable Labs grants Cures Within Reach commercial rights to pediatric leukemia compound

January 25, 2019 6:28 PM UTC

Notable Labs Inc. (Foster City, Calif.) granted non-profit Cures Within Reach (Chicago, Ill.) commercial rights to ND-1000 for pediatric leukemia.

The company said the first clinical trial of ND-1000 is slated to start in mid-2019 at the University of Kansas Medical Center in pediatric patients with chronic lymphocytic leukemia (CLL). ND-1000 is a combination of an undisclosed generic drug and an undisclosed natural product...

BCIQ Company Profiles

Notable Labs Ltd.